SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 190.35+3.0%10:44 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jayhawk969 who wrote (22932)7/8/1998 5:41:00 PM
From: Henry Niman   of 32384
 
Next week LGND will also be discussing rexinoids at the Signal Transduction meeting in San Diego:

A Pharmacological Dissection of RXR Signaling
Pathways with Rexinoids

Richard A. Heyman, Ph.D., Senior Director, Retinoid
Research, Ligand Pharmaceuticals

Receptor X receptors (RXR) play a central role in the regulation
of many intracellular receptor signaling pathways. To examine
signaling pathways mediated by RXR and its partners, we have
designed and synthesized a series of synthetic ligands that
bind RXR and modulate its transcriptional properties. These
rexinoids have been used as pharmacological tools in a
multitude of molecular, cellular and animal models. In animal
models of Type II diabetes, RXR agonists function as insulin
sensitizers significantly decreasing hyperglycemia and
hyperinsulinemia. These data suggest that activation of the
RXR:PPARg heterodimer with rexinoids may provide a new
treatment for insulin resistance. In a carcinogen induced breast
cancer model, RXR agonists are as effective as tamoxifen in
the prevention and therapy of mammary carcinomas. The
ability of RXR rexinoids to alter transcriptional signaling of
distinct endocrine signaling pathways offers new opportunities
for the treatment of different disease states.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News